A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer

Summary Breast cancer is a heterogeneous disease. Tumor cells and associated healthy cells form ecosystems that determine disease progression and response to therapy. To characterize features of breast cancer ecosystems and their associations with clinical data, we analyzed 144 human breast tumor and 50 non-tumor tissue samples using mass cytometry. The expression of 73 proteins in 26 million cells was evaluated using tumor and immune cell-centric antibody panels. Tumors displayed individuality in tumor cell composition, including phenotypic abnormalities and phenotype dominance. Relationship analyses between tumor and immune cells revealed characteristics of ecosystems related to immunosuppression and poor prognosis. High frequencies of PD-L1+ tumor-associated macrophages and exhausted T cells were found in high-grade ER+ and ER− tumors. This large-scale, single-cell atlas deepens our understanding of breast tumor ecosystems and suggests that ecosystem-based patient classification will facilitate identification of individuals for precision medicine approaches targeting the tumor and its immunoenvironment.

[1]  Roland Eils,et al.  circlize implements and enhances circular visualization in R , 2014, Bioinform..

[2]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[4]  Eli R. Zunder,et al.  Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm , 2015, Nature Protocols.

[5]  J. Infante,et al.  Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies , 2014, Drugs.

[6]  Geoffrey E. Hinton,et al.  Reducing the Dimensionality of Data with Neural Networks , 2006, Science.

[7]  E. Asselin,et al.  Akt isoforms regulate intermediate filament protein levels in epithelial carcinoma cells , 2010, FEBS letters.

[8]  C. Sotiriou,et al.  Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer , 2016, Oncoimmunology.

[9]  Sean C. Bendall,et al.  Normalization of mass cytometry data with bead standards , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[10]  Angela E. Leek,et al.  Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies , 2018, Cancer cell.

[11]  O. Ornatsky,et al.  Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. , 2009, Analytical chemistry.

[12]  Ambrose J. Carr,et al.  Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment , 2018, Cell.

[13]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[14]  Peter P. Lee,et al.  Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression , 2018, Nature Communications.

[15]  Sean C. Bendall,et al.  Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis , 2015, Cell.

[16]  George A. Dominguez,et al.  CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients. , 2018, JCI insight.

[17]  Sean C. Bendall,et al.  A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging , 2018, Cell.

[18]  Jeong Eon Lee,et al.  Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer , 2017, Nature Communications.

[19]  Lisa M. Arendt,et al.  Obesity reversibly depletes the basal cell population and enhances mammary epithelial cell estrogen receptor alpha expression and progenitor activity , 2017, Breast Cancer Research.

[20]  M. Bentires-Alj,et al.  Mechanism-based cancer therapy: resistance to therapy, therapy for resistance , 2014, Oncogene.

[21]  Sean C. Bendall,et al.  Multiplexed ion beam imaging of human breast tumors , 2014, Nature Medicine.

[22]  Sherene Loi,et al.  Checkpoint blockade in the treatment of breast cancer: current status and future directions , 2018, British Journal of Cancer.

[23]  Toby C. Cornish,et al.  PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. , 2016, Human pathology.

[24]  H. Lee,et al.  Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling , 2017, PloS one.

[25]  Stephen T. C. Wong,et al.  EMT is not required for lung metastasis but contributes to chemoresistance , 2016 .

[26]  R. Gelber,et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  A. Børresen-Dale,et al.  The Life History of 21 Breast Cancers , 2012, Cell.

[28]  Inna Kuperstein,et al.  Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. , 2018, Cancer cell.

[29]  Mark D. Robinson,et al.  Comparison of Clustering Methods for High-Dimensional Single-Cell Flow and Mass Cytometry Data , 2016, bioRxiv.

[30]  I. Ellis,et al.  The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice , 2014, Histopathology.

[31]  Marco Laumanns,et al.  CellCycleTRACER accounts for cell cycle and volume in mass cytometry data , 2018, Nature Communications.

[32]  David M. Simcha,et al.  Tackling the widespread and critical impact of batch effects in high-throughput data , 2010, Nature Reviews Genetics.

[33]  Nikesh Kotecha,et al.  Web‐Based Analysis and Publication of Flow Cytometry Experiments , 2010, Current protocols in cytometry.

[34]  Geoffrey E. Hinton,et al.  Visualizing Data using t-SNE , 2008 .

[35]  M. Dickler,et al.  Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies. , 2016, Endocrine-related cancer.

[36]  M. Hung,et al.  The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer , 2016, Cancer and Metastasis Reviews.

[37]  S. Barsky,et al.  The myoepithelial defense: a host defense against cancer. , 1997, Medical hypotheses.

[38]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[39]  Michael B. Stadler,et al.  An Immune Atlas of Clear Cell Renal Cell Carcinoma , 2017, Cell.

[40]  M. Dieci,et al.  The immune system and hormone-receptor positive breast cancer: Is it really a dead end? , 2016, Cancer treatment reviews.

[41]  Martin Fodslette Møller,et al.  A scaled conjugate gradient algorithm for fast supervised learning , 1993, Neural Networks.

[42]  Bernd Bodenmiller,et al.  AirLab: a cloud-based platform to manage and share antibody-based single-cell research , 2016, Genome Biology.

[43]  Benjamin D. Greenbaum,et al.  Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses , 2017, Cell.

[44]  Mark D. Robinson,et al.  Compensation of Signal Spillover in Suspension and Imaging Mass Cytometry , 2018, Cell systems.

[45]  K. Polyak,et al.  Intra-tumour heterogeneity: a looking glass for cancer? , 2012, Nature Reviews Cancer.

[46]  Paul J. Hoover,et al.  Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma , 2018, Cell.

[47]  L. Nardo,et al.  Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. , 2016, The Journal of clinical investigation.

[48]  Sean C. Bendall,et al.  Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum , 2011, Science.

[49]  Jimmy Ba,et al.  Adam: A Method for Stochastic Optimization , 2014, ICLR.

[50]  Sandro Santagata,et al.  Taxonomy of breast cancer based on normal cell phenotype predicts outcome. , 2014, The Journal of clinical investigation.

[51]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[52]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[53]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[54]  E. Wherry,et al.  Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.

[55]  C. Eaves,et al.  Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue , 2001, Breast Cancer Research and Treatment.

[56]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[57]  L. Hubert,et al.  Comparing partitions , 1985 .

[58]  C. Barrios,et al.  Optimal management of hormone receptor positive metastatic breast cancer in 2016 , 2015, Therapeutic advances in medical oncology.

[59]  R. Weinberg,et al.  Tumor-host interactions: a far-reaching relationship. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  I. Amit,et al.  Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma , 2019, Cell.

[61]  J. Visvader,et al.  Mammary stem cells and the differentiation hierarchy: current status and perspectives , 2014, Genes & development.

[62]  R. Straub,et al.  The complex role of estrogens in inflammation. , 2007, Endocrine reviews.

[63]  Geoffrey E. Hinton,et al.  Deep Learning , 2015, Nature.

[64]  Ahmedin Jemal,et al.  Global Cancer in Women: Burden and Trends , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[65]  J. Buhmann,et al.  Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry , 2014, Nature Methods.

[66]  J. Pollard,et al.  Targeting macrophages: therapeutic approaches in cancer , 2018, Nature Reviews Drug Discovery.